Murex challenges Chiron's monopoly
This article was originally published in Clinica
Executive Summary
Chiron has re-amended its UK HCV patent by deleting claims covering non-HCV products, thereby validating the patent. The UK Court of Appeals had found on November 2nd that the patent was only partially valid but at the hearing on November 7th to address outstanding hepatitis C patent litigation issues (see Clinica No 679, p 12), the Court allowed Chiron to re-amend the patent. As a result, the Court ruled that Murex and UBI still infringe the re-amended patent and a damage enquiry will follow.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.